The race to harness artificial intelligence for biological breakthroughs just got a $400.0M boost. Chai Discovery, a startup building frontier AI to predict and reprogram the interactions between biochemical molecules, has closed its Series C funding round.
The substantial capital infusion drew a formidable syndicate of investors, including Index Ventures, Kleiner Perkins, Sequoia Capital, and even OpenAI. They were joined by firms like Thrive Capital, Oak HC/FT, Menlo Ventures, General Catalyst, and Bain Capital Ventures, among others, signaling strong confidence in the company's ambitious scientific mission.
